Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06128408
Other study ID # 2023-6-002
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date December 1, 2023
Est. completion date October 13, 2024

Study information

Verified date October 2023
Source Peking University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Previous long-term follow-up studies on patients with first-episode schizophrenia have shown that up to 30% of patients who have never received antipsychotic medication treatment do not experience symptom relief or have poor treatment response after standard antipsychotic medication treatment, becoming treatment-resistant schizophrenia (TRS). Moreover, in long-term follow-up, patients with treatment-resistant schizophrenia from the illness onset (TRO) account for 80% of all TRS patients. Preliminary studies abroad have found that TRO patients have characteristics such as early age of onset, male predominance, prominent negative symptoms, high proportion of positive family history, and long duration of untreated psychosis, but there is still no consistent conclusion on the pathological mechanisms. There is currently no research on this type of patient in China, and there are difficulties in early diagnosis of TRO patients in clinical practice. This study aims to establish a TRO prediction model by integrating data on demographics, disease characteristics, psychopathology, social function, and neurocognition from a cohort of patients with first-episode schizophrenia. Mathematical modeling methods such as K-Means/SVM and convolutional neural networks will be used. Therefore, in patients with untreated first-episode schizophrenia, early and accurate identification of TRO patients at the initial diagnosis stage and treatment with clozapine is particularly important for potentially shortening the treatment period and reducing the personal and societal burden of TRO patients. Based on the progress of existing research and the previous work of the research team, we speculate that TRO patients have unique clinical features. This project will establish a TRO prediction model based on multidimensional clinical data using mathematical modeling methods. From a clinical application perspective, the study selects TRO model prediction factors based on existing clinical assessment methods, making the model highly clinically applicable and generalizable. By establishing a TRO prediction model, not only can high-risk TRO patients be identified early in the initial diagnosis stage, enabling appropriate clinical treatment interventions, but it can also provide new insights into the future clinical treatment of TRO, promote the development of early and personalized precision identification and treatment of TRO, and improve long-term prognosis and reduce the burden of the disease for patients.


Description:

Research steps: (1) First, based on the applicant's project funded by the National Natural Science Foundation of China (National Natural Science Foundation: Precise Identification and Treatment of Treatment-Resistant First-Episode Schizophrenia), treatment-resistant first-episode schizophrenia patients (TRO) and non-treatment-resistant first-episode schizophrenia patients (None-TRO) will be included. The demographic information, disease characteristics, psychopathology, social functioning, and neurocognition data of the patients will be collected. This includes scores from the Positive and Negative Syndrome Scale (PANSS), Bech-Rafaelsen Mania Scale (BRMS), Calgary Depression Scale for Schizophrenia (CDSS), Insight into Treatment Adherence Questionnaire (ITAQ), Perceived Stress Scale- Chinese Version (PSS-CV), Childhood Trauma Questionnaire (CTQ), Abnormal Involuntary Movement Scale (AIMS), Rating Scale for Extrapyramidal Side Effects (RSESE), Clinical Global Impressions Scale (CGI), Medication Adherence Rating Scale (MARS), UKU Side Effect Rating Scale, Personal and Social Performance Scale (PSP), Premorbid Adjustment Scale (PAS), and Computerized Battery of Cognitive Tests (CBCT). All data will be anonymized and will not involve the personal privacy of the participants. (2) For TRO patients, demographic information, disease characteristics, psychopathology, social functioning, and neurocognition data will be integrated. Mathematical modeling methods such as K-Means/SVM and Convolutional Neural Networks will be used to try to establish a TRO prediction model, with predictive factors obtained through literature review, expert consultation, and data analysis. Treatment-resistant schizophrenia: After 6 weeks of treatment with two second-generation antipsychotic drugs at an adequate dose (minimum dose for acute treatment of schizophrenia as stated in the antipsychotic drug instructions or equivalent dose of 600mg chlorpromazine), no clinical improvement is observed (CGI-S ≥ 4 or PANSS reduction rate < 50%).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 300
Est. completion date October 13, 2024
Est. primary completion date October 12, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: 1. Having a diagnosis of schizophrenics based on the patient edition of the Structured Clinical Interview for Axis I Diagnostic and Statistical Manual-IV Axis I Disorders (SCID). 2. Age 18-45 years. 3. First episode of schizophrenia. 4. Course of disease = 3 years. 5. Previous continuous medication = 4 weeks, cumulative intermittent medication = 12 weeks. 6. Be able to understand the interview content and sign written informed consent. Exclusion Criteria: 1. Previous history of major physical diseases. 2. Previous substance abuse or dependence. 3. Contraindications to olanzapine, risperidone or aripiprazole.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
risperidone, olanzapine, aripiprazole
Participants from the retrospective cohort were randomly assigned to one of the three drug groups of risperidone, olanzapine and aripiprazole for a period of 1 years of treatment.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Peking University

Outcome

Type Measure Description Time frame Safety issue
Primary treatment-resistant schizophrenia Treated with sufficient dosage of two types of second-generation antipsychotic medications (at least the minimum dose for acute phase treatment of schizophrenia or an equivalent dose of 600mg chlorpromazine) for 6 weeks, but did not achieve clinical improvement (CGI-S=4 or PANSS reduction rate <50%). From December 1, 2023 to October 12, 2024
See also
  Status Clinical Trial Phase
Completed NCT03076346 - Neural Biomarkers of Clozapine Response
Completed NCT03148639 - Virtual Reality Therapy for Treatment-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT01431326 - Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Recruiting NCT06270108 - The Role of Glutamatergic Function in the Pathophysiology of Treatment-resistant Schizophrenia Early Phase 1
Not yet recruiting NCT06060886 - Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis Phase 4
Recruiting NCT05694000 - Hippocampus DBS in Treatment-resistant Schizophrenia N/A
Completed NCT01105481 - Amisulpride Augmentation Therapy for Clozapine-resistant Schizophrenic Patients Phase 4
Recruiting NCT02361554 - Deep Brain Stimulation in Treatment Resistant Schizophrenia N/A
Recruiting NCT05299749 - Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory Hallucinations N/A
Completed NCT03585127 - Avatar Therapy in Comparison to Cognitive Behavioral Therapy for Treatment-resistant Schizophrenia N/A
Not yet recruiting NCT05259306 - Low-Intensity Focused Ultrasound Neuromodulation of the Mediodorsal Thalamus for Treatment-Resistant Schizophrenia N/A
Terminated NCT03230864 - Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia Phase 3
Recruiting NCT05337904 - Deep Brain Stimulation Recovery in Treatment-Resistant Schizophrenia N/A
Terminated NCT03868839 - Telmisartan Pilot Study on Treatment Resistant Schizophrenia Phase 2
Not yet recruiting NCT04528095 - SMART Design to Compare Antipsychotic Treatments in Treatment-Resistant Schizophrenia Phase 3
Recruiting NCT05074732 - Dundrum Forensic Redevelopment Evaluation Study: D-FOREST Study.
Completed NCT03983018 - Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019) Phase 1
Recruiting NCT05741502 - An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine Phase 4
Recruiting NCT04054778 - Comparaison of Avatar Therapy to Cognitive Behavioral Therapy in Schizophrenia With Treatment Refractory Hallucinations N/A